Recently we've had a run of lymphomas where we had two lymphomas, CLL, and mantle cell lymphoma in the same person, and we wouldn't have caught it had we not looked for it.

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. ... mantle cell lymphoma; This article examines the differences between CLL and T-cell PLL.

Maddocks: When I started, I did a lot of work in CLL (chronic lymphocytic leukemia). But often there are patients who are diagnosed initially, and there's a question of CLL or mantle cell, or they ...

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ... Mantle cell lymphoma (MCL) is a rare and fast-growing cancer. About 6% of all non-Hodgkin's lymphomas are this type.

New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant ...

Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma ... The BCL-2 inhibitor venetoclax has approval in multiple countries as single-agent therapy for CLL and untreated acute myelogenous ...

Mantle cell lymphoma. ... as a single treatment and in combination with standard-of-care chemoimmunotherapy for patients with multiple B-cell blood cancers, including CLL, ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients with relapsed or refractory mantle cell lymphoma in a phase 1/2 study.In ...

Meanwhile, Calquence’s combination with bendamustine and rituximab recently showed a positive overall survival trend against the chemoimmunotherapy in previously untreated mantle cell lymphoma.

The Food and Drug Administration (FDA) has granted Priority Review to acalabrutinib for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), plus bendamustine and rituximab, to treat adults with previously ...

AstraZeneca announced on May 6, 2025 that its Calquence (acalabrutinib), a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK), was approved in the European Union in combination ...